Rodríguez-Santos O, Reyes-Almaguer MC

Language: Spanish
References: 20
Page: 86-92
PDF size: 324.65 Kb.

ABSTRACT

The efficacy and safety of sublingual immunotherapy (SLIT) was assessed in patients from Previsora Camagüey Clinic, who were diagnosed with allergic rhinitis and asthma. A retrospective case-control study was carried out. Cases and controls were selected in 62 children from 6 to 24 months of age: 34 children had used ITSL (cases); the other 28 children received only environmental prevention (controls). All children used medicines in the crisis stage. Quality of life questionnaires for rhinitis (RQLQm) and asthma (AQLQm) were applied. Medicine consumption and frequency of crises were analyzed. A subjective assessment of children health before and after the treatment was performed to relatives and physicians. Local and systemic reactions to SLIT were evaluated. An increase in the score of life quality questionnaires was detected (p=0.033). The medicine consumption was more reduced in cases than in controls (p=0.003). The frequency of respiratory symptomatology decreased (p=0.029). The score of subjective assessment was negative before treatment. After the treatment 85% of cases got 5 points, while the remaining 15% of cases obtained between 3 and 4 points. In the control group 55% of patients obtained 5 points, 10% of evaluated children between 3 and 4, and 5% between 0 and 2 points (p=0.011). Two mild adverse reactions to the SLIT were reported. Results showed that the sublingual immunotherapy with mites in children under 2 years old with rhinitis and asthma is effective and safe.

REFERENCES

1. Declaración de Helsinki de la Asociación Médica Mundial. ARBOR Ciencia, Pensamiento y Cultura 2008;730:349-52.

2. OPS. Pautas éticas internacionales para la investigación biomédica en seres humanos. Programa Regional de Bioética OPS/OMS. Washington: OPS-WHO; 2013.

3. Li P, Li Q, Huang Z, Chen W, Lu Y, Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol 2014;4(10):796-801.

4. Trebuchon F, Lhéritier-Barrand M, David M, Demoly P. Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens. Clin Transl Allergy 2014;4:15. Disponible en: doi:10.1186/2045-7022-4-15.

5. de Bot CM, Moed H, Berger MY, Röder E, Hop WC, de Groot H, et al. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol 2012;23(2):150-8.

6. Corzo JL, Carrillo T, Pedemonte C, Plaza Martin AM, Martín Hurtado S, Dige E, et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol 2014;24(3):154-61.

7. Luo R, Liu W, Wang J, Chen Y, Sun C, Zhou L, et al. Role of BAFF in pediatric patients with allergic rhinitis during sublingual immunotherapy. Eur J Pediatr 2014;173(8):1033-40.

8. Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Respir Med 2013;107(9):1322-9.

9. Dalkan C, Galip N, Tekguc H, Cobanoglu N, Bahceciler N. High prevalence of allergy in North Cypriot children. Paediatr Int Child Health 2014;34(1):37-42.

10. Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E, et al. New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis. Biologics 2014;8:221-6.

11. Rodríguez O, Labrada A, Célio R, Aboukhair F, Meli VR, Barata HJ, et al. Comparación de la potencia de extractos alergénicos de ácaros en pacientes con asma y rinitis alérgica. VacciMonitor 2012;21(1):25-9.

12. Juniper EF, Svensson K, Mork AC, Stahl E. Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older. Health Qual Life Outcomes 2005;3:58. Disponible en: doi:10.1186/1477-7525-3-58

13. Chen H, Cisternas MG, Katz PP, Omachi TA, Trupin L, Yelin EH, et al. Evaluating quality of life in patients with asthma and rhinitis: English adaptation of the rhinasthma questionnaire. Ann Allergy Asthma Immunol 2011;106(2):110-8.

14. Nascimento-Silva MG, Solé D. Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Allergol Immunopathol 2001;29(4):111-8.

15. Rodríguez SO. Inmunoterapia sublingual en rinitis alérgica y asma en niños de dos a cinco años sensibilizados con ácaros. Rev Alerg Mex 2008;55(2):71-5.

16. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther 2013;13(11):1543-56.

17. Tao L, Shi B, Shi G, Wan H. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. Clin Respir J 2014;8(2):192-205.

18. Lin Z, Zhou L, Luo X, Xia W, Chen D, Xu R, et al. Suppression of TIM-1 predicates clinical efficacy of sublingual immunotherapy for allergic rhinitis in children. Int J Pediatr Otorhinolaryngol 2013;77(8):1345-9.

19. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132(6):1322-36.

20. Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organization Journal 2014,7:21. Disponible en: doi:10.1186/1939-4551-7-21